OBN, the membership organisation supporting the UK’s innovative life sciences companies, announces the following changes to its Board.
Bill Fleming has been appointed the new Chairman of the Board of Directors, replacing Sally Waterman, who has served on the Board of Directors since 2014. Bill Fleming has strong management and board of director experience, having served on OBN’s Board as a Non-Executive Director since April 2017.
Bill Fleming said, “I am honoured to pick-up the baton of Chairman and look forward to continuing my strong relationship with OBN, supporting an immensely talented and innovative team, delivering true value to its members.”
David Browning was welcomed to OBN in the position of non-executive director on 20 December 2018, applying 37 years of healthcare innovation experience, with a keen focus on improving standards of care and health economic outcomes.
David currently serves as CEO of Oxford Cancer Biomarkers, implementing the development and global commercialisation of diagnostic platforms for precision medicine. He is also a Non-Executive Director with Digital Care Planning, an Imperial College spin-out, focussing on enabling people to take more control of their medical provision. He has advised numerous successful businesses across health and life-sciences and nanotechnology.
David has previously held senior positions within the BioCity Group and MediCity, Philips Innovation, Amersham International, J&J, IGEN International and Oxonica Healthcare. David started his career as a Biomedical Scientist within the NHS, gaining his MSc in Biochemical Immunology.
David Browning said, “I have been an advocate of OBN for many years and am delighted to join the Board at this exciting time for both the organisation and the life sciences industry – we face both tremendous opportunities and significant challenges in the near future and I look forward to working with the OBN team and our members.”
John Harris, OBN’s CEO, commented: “Given Bill’s in-depth knowledge of OBN, both as a Non-Executive Director and as a member of OBN’s Investment and Tax Special Interest Group, I am delighted that he has agreed to take on the role of Chairman of OBN’s Board. With his transition to Chairman of the Board, Bill will take a more active role in providing leadership to the organisation’s officers and executives.
Additionally, I am pleased to welcome David Browning to the Board. His wealth of knowledge and experience with not-for-profits, start-ups and large corporations will be invaluable to the Board. David has attended many OBN events and Oxford Cancer Biomarkers, of which he is the CEO, are long-standing OBN members.
I would also like to take this opportunity to thank Sally Waterman for her support and advice during her tenure. Sally has been a great ally of OBN for many years and her support and dedication to OBN and its Board has been greatly appreciated. We wish her well with her future endeavours; no doubt we will continue to see Sally at our networking events.”
Sally Waterman said: “It has been a pleasure to have been part of OBN’s journey from a regionally-focused organisation to one that, alongside others, supports life science companies throughout the UK. Under the leadership of John Harris, OBN has become an effective and efficient organisation with a clear vision for the future which, with the support of an experienced Board of Directors, I look forward to seeing realised.”
More career news on Pharmafield